






Supplemental Figure 1. (A) Chemical structure of lorlatinib. (B) Micrographs of cells treated with lorlatinib as indicated dose for 48 h.



Supplemental Figure 2. The quantification and statistical analysis were shown the autophagosomes of H3122 and H2228 cells which were treated with Rap (500nM) or serum deprivation. Rap:rapamycin. *, $p < 0.01$



Supplemental Figure 3. Lorlatinib-induced autophagy protects cells from apoptosis.

(A) Cell viability cck-8 assay for cells treated with the indicated concentrations of lorlatinib with or without 3-MA(100μM) for 48 h. (B) Cells were treated by Lorlatinib(10nM) with or without 3-MA (100μM) for 48 h. Western blot analysis was performed to the indicated antibody. GAPDH was included as a loading control. (C) Cells were treated by Lorlatinib(10nM) with or without 3-MA (100μM) for 48 h, then stained with AO/EB. Lor, lorlatinib. *,p<0.01